In a research report published today, Roth Capital analyst Scott Henry maintained a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $160 price …
In a research report issued yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals (SLXP) with a $157 price target, following a …
In a research report released yesterday, William Blair analyst Tim Lugo maintained an Outperform rating on Salix Pharmaceuticals Ltd. (SLXP) with a $157 …
In a research note released today, Canaccord analyst Corey Davis reiterated coverage with a Buy rating on shares of Salix Pharmaceuticals (SLXP) and a $161.00 price target, following yesterday’s news of a definitive merger agreement …
In a research report released yesterday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Salix Pharmaceuticals (SLXP) and a price target of $145.00 a share, representing a potential upside of …
